Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension. Read why I'm ...

Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) shares gapped up before the market opened on Friday . The stock had previously closed at $45.69, but opened at $47.00. Tectonic Therapeutic shares ...

Tectonic Therapeutic, Inc. is headquartered just outside of Boston in Watertown, MA. The current iteration of the company was formed late this spring when it reversed merged with Avrobio ...

Tectonic Therapeutic has a 12 month low of $12.12 and a 12 month high of $53.34. The company has a market cap of $701.21 million, a P/E ratio of -8.07 and a beta of 2.60. The firm’s 50-day ...

Tiago Fauth has given his Buy rating due to a combination of factors that highlight Tectonic Therapeutic’s promising potential. The recent Phase 1a results for their drug TX45 were notably ...

WATERTOWN, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) a clinical stage biotechnology company focused on the discovery and development of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

With a market capitalization of $766.4 million and... ByInvesting.com • 52 minutes ago Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential ...